INOVIO PHARMACEUTICALS INC (INO) Stock Fundamental Analysis

NASDAQ:INO • US45773H4092

1.73 USD
+0.01 (+0.58%)
At close: Feb 20, 2026
1.73 USD
0 (0%)
After Hours: 2/20/2026, 8:00:01 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to INO. INO was compared to 521 industry peers in the Biotechnology industry. INO may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, INO is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • In the past year INO has reported negative net income.
  • INO had a negative operating cash flow in the past year.
  • INO had negative earnings in each of the past 5 years.
  • In the past 5 years INO always reported negative operating cash flow.
INO Yearly Net Income VS EBIT VS OCF VS FCFINO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100M -200M -300M

1.2 Ratios

  • INO has a Return On Assets of -155.78%. This is amonst the worse of the industry: INO underperforms 85.22% of its industry peers.
Industry RankSector Rank
ROA -155.78%
ROE N/A
ROIC N/A
ROA(3y)-84.69%
ROA(5y)-69.23%
ROE(3y)-132.51%
ROE(5y)-101.92%
ROIC(3y)N/A
ROIC(5y)N/A
INO Yearly ROA, ROE, ROICINO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -1K -2K -3K

1.3 Margins

  • INO does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
INO Yearly Profit, Operating, Gross MarginsINO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10K -20K -30K -40K -50K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

0

2. Health

2.1 Basic Checks

  • INO does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for INO has been increased compared to 1 year ago.
  • Compared to 5 years ago, INO has more shares outstanding
  • There is no outstanding debt for INO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
INO Yearly Shares OutstandingINO Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
INO Yearly Total Debt VS Total AssetsINO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

2.2 Solvency

  • INO has an Altman-Z score of -40.30. This is a bad value and indicates that INO is not financially healthy and even has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of -40.30, INO is doing worse than 89.83% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -40.3
ROIC/WACCN/A
WACC8.55%
INO Yearly LT Debt VS Equity VS FCFINO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M

2.3 Liquidity

  • A Current Ratio of 0.79 indicates that INO may have some problems paying its short term obligations.
  • INO has a Current ratio of 0.79. This is amonst the worse of the industry: INO underperforms 87.33% of its industry peers.
  • INO has a Quick Ratio of 0.79. This is a bad value and indicates that INO is not financially healthy enough and could expect problems in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 0.79, INO is doing worse than 86.95% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.79
Quick Ratio 0.79
INO Yearly Current Assets VS Current LiabilitesINO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. Growth

3.1 Past

  • INO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 44.79%, which is quite impressive.
  • Looking at the last year, INO shows a very negative growth in Revenue. The Revenue has decreased by -10.55% in the last year.
  • The Revenue for INO have been decreasing by -44.44% on average. This is quite bad
EPS 1Y (TTM)44.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%2.25%
Revenue 1Y (TTM)-10.55%
Revenue growth 3Y-50.31%
Revenue growth 5Y-44.44%
Sales Q2Q%N/A

3.2 Future

  • INO is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 17.32% yearly.
  • The Revenue is expected to grow by 356.19% on average over the next years. This is a very strong growth
EPS Next Y42.3%
EPS Next 2Y27.84%
EPS Next 3Y25%
EPS Next 5Y17.32%
Revenue Next Year-27.29%
Revenue Next 2Y1197.67%
Revenue Next 3Y796.87%
Revenue Next 5Y356.19%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
INO Yearly Revenue VS EstimatesINO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 50M 100M 150M 200M 250M
INO Yearly EPS VS EstimatesINO Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 -5 -10 -15

More info and screens

Find the best growth stocksShow best growing peers

1

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for INO. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for INO. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
INO Price Earnings VS Forward Price EarningsINO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
INO Per share dataINO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1 -1.5 -2

4.3 Compensation for Growth

  • A more expensive valuation may be justified as INO's earnings are expected to grow with 25.00% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y27.84%
EPS Next 3Y25%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • INO does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

INOVIO PHARMACEUTICALS INC

NASDAQ:INO (2/20/2026, 8:00:01 PM)

After market: 1.73 0 (0%)

1.73

+0.01 (+0.58%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-10
Earnings (Next)03-16
Inst Owners36.03%
Inst Owner Change-0.19%
Ins Owners0.4%
Ins Owner Change0%
Market Cap118.85M
Revenue(TTM)182.30K
Net Income(TTM)-108.09M
Analysts80
Price Target8.73 (404.62%)
Short Float %18.2%
Short Ratio8.02
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-51.35%
Min EPS beat(2)-103.56%
Max EPS beat(2)0.86%
EPS beat(4)3
Avg EPS beat(4)-7.17%
Min EPS beat(4)-103.56%
Max EPS beat(4)44.99%
EPS beat(8)5
Avg EPS beat(8)-3.62%
EPS beat(12)6
Avg EPS beat(12)-4.36%
EPS beat(16)7
Avg EPS beat(16)-6.74%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)12.14%
PT rev (3m)14.64%
EPS NQ rev (1m)0%
EPS NQ rev (3m)11%
EPS NY rev (1m)0%
EPS NY rev (3m)-20.91%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-1.88%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 651.95
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-2.49
EYN/A
EPS(NY)-1.46
Fwd EYN/A
FCF(TTM)-1.3
FCFYN/A
OCF(TTM)-1.3
OCFYN/A
SpS0
BVpS-0.11
TBVpS-0.11
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -155.78%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-84.69%
ROA(5y)-69.23%
ROE(3y)-132.51%
ROE(5y)-101.92%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 10.48%
Cap/Sales 85.63%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.79
Quick Ratio 0.79
Altman-Z -40.3
F-Score3
WACC8.55%
ROIC/WACCN/A
Cap/Depr(3y)20.92%
Cap/Depr(5y)27.95%
Cap/Sales(3y)90.66%
Cap/Sales(5y)72.37%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)44.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%2.25%
EPS Next Y42.3%
EPS Next 2Y27.84%
EPS Next 3Y25%
EPS Next 5Y17.32%
Revenue 1Y (TTM)-10.55%
Revenue growth 3Y-50.31%
Revenue growth 5Y-44.44%
Sales Q2Q%N/A
Revenue Next Year-27.29%
Revenue Next 2Y1197.67%
Revenue Next 3Y796.87%
Revenue Next 5Y356.19%
EBIT growth 1Y24.53%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y33.67%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y33.54%
OCF growth 3YN/A
OCF growth 5YN/A

INOVIO PHARMACEUTICALS INC / INO FAQ

Can you provide the ChartMill fundamental rating for INOVIO PHARMACEUTICALS INC?

ChartMill assigns a fundamental rating of 1 / 10 to INO.


What is the valuation status of INOVIO PHARMACEUTICALS INC (INO) stock?

ChartMill assigns a valuation rating of 1 / 10 to INOVIO PHARMACEUTICALS INC (INO). This can be considered as Overvalued.


Can you provide the profitability details for INOVIO PHARMACEUTICALS INC?

INOVIO PHARMACEUTICALS INC (INO) has a profitability rating of 0 / 10.


Can you provide the financial health for INO stock?

The financial health rating of INOVIO PHARMACEUTICALS INC (INO) is 0 / 10.


What is the expected EPS growth for INOVIO PHARMACEUTICALS INC (INO) stock?

The Earnings per Share (EPS) of INOVIO PHARMACEUTICALS INC (INO) is expected to grow by 42.3% in the next year.